The AML Hub was pleased to speak with Amir Fathi, Massachusetts General Hospital, Boston, US. We asked, How would you treat newly diagnosed induction-eligible patients with acute myeloid leukemia?

Fathi highlights that to determine eligibility for intensive cytotoxic chemotherapy, patient's fitness, comorbidities, and functional status are considered. He outlines induction chemotherapy regimens and highlights the two step approach to newly diagnosed AML; intensive chemotherapy, followed by consolidation. Finally, Fathi explains that for less robust patients a gentler regimen including hypomethylating agents or BCL-2 inhibitors can be used as an alternative.

свернуть